[HTML][HTML] Coronavirus disease (COVID-19): a scoping review
M Lv, X Luo, J Estill, Y Liu, M Ren, J Wang… - …, 2020 - eurosurveillance.org
Background In December 2019, a pneumonia caused by a novel coronavirus (SARS-CoV-2)
emerged in Wuhan, China and has rapidly spread around the world since then. Aim This …
emerged in Wuhan, China and has rapidly spread around the world since then. Aim This …
Evidence-based management of the critically ill adult with SARS-CoV-2 infection
RR Chivukula, JH Maley… - Journal of Intensive …, 2021 - journals.sagepub.com
Human infection by the novel viral pathogen SARS-CoV-2 results in a clinical syndrome
termed Coronavirus Disease 2019 (COVID-19). Although the majority of COVID-19 cases …
termed Coronavirus Disease 2019 (COVID-19). Although the majority of COVID-19 cases …
Tocilizumab for treatment of mechanically ventilated patients with COVID-19
EC Somers, GA Eschenauer, JP Troost… - Clinical Infectious …, 2021 - academic.oup.com
Background Severe coronavirus disease 2019 (COVID-19) can manifest in rapid
decompensation and respiratory failure with elevated inflammatory markers, consistent with …
decompensation and respiratory failure with elevated inflammatory markers, consistent with …
[HTML][HTML] Characteristics, treatment, outcomes and cause of death of invasively ventilated patients with COVID-19 ARDS in Milan, Italy
Objective: Describe characteristics, daily care and outcomes of patients with coronavirus
disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). Design: Case series …
disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS). Design: Case series …
Efficacy and safety of sarilumab in hospitalized patients with coronavirus disease 2019: a randomized clinical trial
S Sivapalasingam, DJ Lederer, R Bhore… - Clinical Infectious …, 2022 - academic.oup.com
Background Open-label platform trials and a prospective meta-analysis suggest efficacy of
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 …
anti–interleukin (IL)-6R therapies in hospitalized patients with coronavirus disease 2019 …
[HTML][HTML] Efficacy and safety of current medications for treating severe and non-severe COVID-19 patients: an updated network meta-analysis of randomized placebo …
Q Cheng, J Chen, Q Jia, Z Fang, G Zhao - Aging (albany NY), 2021 - ncbi.nlm.nih.gov
Background: Many recent studies have investigated the role of drug interventions for
coronavirus disease 2019 (COVID-19) infection. However, an important question has been …
coronavirus disease 2019 (COVID-19) infection. However, an important question has been …
A collaborative multidisciplinary approach to the management of coronavirus disease 2019 in the hospital setting
RR Razonable, KM Pennington, AM Meehan… - Mayo Clinic …, 2020 - Elsevier
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes
coronavirus disease 2019 (COVID-19), which presents an unprecedented challenge to …
coronavirus disease 2019 (COVID-19), which presents an unprecedented challenge to …
[HTML][HTML] Monoclonal antibodies as COVID-19 prophylaxis therapy in immunocompromised patient populations
The objective of this review was to examine the latest literature regarding the effectiveness
of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient …
of monoclonal antibodies as COVID-19 prophylaxis therapy for immunocompromised patient …
Ten things you need to know about intensive care unit management of mechanically ventilated patients with COVID-19
Introduction: The ongoing pandemic caused by severe acute respiratory syndrome
coronavirus-2 (SARS-CoV-2) has posed important challenges for clinicians and health-care …
coronavirus-2 (SARS-CoV-2) has posed important challenges for clinicians and health-care …
[HTML][HTML] European society of clinical microbiology and infectious diseases guidelines for coronavirus disease 2019: an update on treatment of patients with mild …
M Bartoletti, O Azap, A Barac, L Bussini… - Clinical Microbiology …, 2022 - Elsevier
Scope Despite the large availability of vaccines, coronavirus disease 2019 (COVID-19),
induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat …
induced by severe acute respiratory syndrome coronavirus 2, continues to be a major threat …